Anti-PTK7 Antibody Patent Application

ChangeBridge: Patent Apps - Therapeutics (A61P)

Published September 6th, 2023

Detected March 23rd, 2026

Summary

The USPTO has published a patent application (US20260078201A1) for an anti-PTK7 antibody. The antibody is described as inhibiting angiogenesis, tumor growth, and cancer, with potential therapeutic applications for angiogenesis-related diseases and PTK7-positive cancers.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260078201A1) filed on September 6, 2023, for an anti-PTK7 antibody. The application details the antibody's potential to inhibit angiogenesis, tumor growth, migration, and invasion of endothelial cells, and to suppress tumor growth in vivo. It is presented as a promising therapeutic agent for angiogenesis-related diseases and PTK7-positive cancers, with potential for humanization and development into novel therapeutics.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signals potential future developments in cancer therapeutics. Companies involved in oncology drug development, particularly those working with antibodies or targeting PTK7, should be aware of this filing as it may impact future intellectual property landscapes and competitive strategies in the pharmaceutical sector.

Source document (simplified)

← USPTO Patent Applications

ANTI-PTK7 ANTIBODY, AND USE THEREOF

Application US20260078201A1 Kind: A1 Mar 19, 2026

Inventors

Seung-Taek LEE, Won-Sik SHIN, Si Won OH, So-Young CHOI, Se-Ra LEE, Sang Gil KIM

Abstract

The present invention relates to an anti-PTK7 antibody and a use thereof. The anti-PTK7 antibody according to the present invention was found to inhibit angiogenesis, as well as the growth, migration, and invasion of human umbilical vein endothelial cells (HUVECs). Additionally, it effectively suppresses tumor growth in vivo, making it a promising therapeutic agent for angiogenesis-related diseases and PTK7-positive cancers. The antibody also has potential for further development as a targeted therapy for intractable cancers, positioning it as a key global therapeutic agent. Furthermore, the antibody can be humanized for clinical applications and serve as a critical component in the development of novel therapeutics.